ATM and neoplasm: Utilizing tumor histomorphology and a mutation spectrum to aid in the diagnosis of pancreatic cancers driven by ATM loss is an intriguing prospect, particularly for patients with a germline ATM variant of unknown significance or equivocal somatic data.